US FDA Signals New COVID-19 Vaccines Could Be Authorized With Just Immunogenicity Studies
As FDA lowers some expectations on timing of booster shots, agency’s outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.
You may also be interested in...
Pfizer scientists said they are having trouble identifying an immune correlate of protection for the company's COVID-19 vaccine, while other scientists expressed optimism that neutralizing antibodies might eventually be able to be used as a correlate, though there were some questions raised about using them for booster decision making.
Drug regulators from five countries have outlined their joint expectations on the data companies must submit for the approval of next-generation COVID-19 vaccines if they opt for immunobridging studies instead of large-scale efficacy trials.
Pfizer has pledged to supply 41% of its COVID-19 vaccine output to developing nations – but warns that these countries still need to sign contracts on time to guarantee supplies.